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Background: The introduction of transcatheter aortic valve replacement (T-AVR) has led to a revival balloon aortic valvuloplasty (BAV) as treatment 
of patients with severe aortic stenosis.
Objectives: This study aimed to determine the outcome of BAV as a stand alone therapy versus BAV as a bridge to transcatheter/surgical AVR.
Methods: A cohort of 472 patients underwent 538 BAV procedures. This cohort was divided into group I; BAV alone 387(81.9%), and group II; BAV 
as bridge 85(18.1%) to (65-T-AVR, 20-surgery). Clinical, hemodynamic, and follow-up mortality data were collected.
Results: There was no significant difference between the two groups in the baseline characteristics (table). The mean increase in aortic valve area 
was 0.39±0.25 in group I and 0.42±0.26 in group II, p=0.33. The decrease in mean gradient was 24.1±13.1 in group I and 27.1±13.8 in group II, 
P=0.06.During median follow up of 183[54-409] days the mortality rate was 55.2.% (214 patients ) in group I and 19(22.3%) in group II during 
median follow-up of 378 [177-690] days, p<0.001. (Figure). 
Conclusion: In high-risk patients with aortic stenosis and temporary contraindications to surgical AVR or T-AVR, BAV may be used as a bridge to 
intervention with good mid-term outcomes. In others, BAV can be safely used but is associated with a poor outcome.
 
